CY1108397T1 - Αντι-ccr4 αντισωμα και θραυσμα αυτου - Google Patents
Αντι-ccr4 αντισωμα και θραυσμα αυτουInfo
- Publication number
- CY1108397T1 CY1108397T1 CY20081101104T CY081101104T CY1108397T1 CY 1108397 T1 CY1108397 T1 CY 1108397T1 CY 20081101104 T CY20081101104 T CY 20081101104T CY 081101104 T CY081101104 T CY 081101104T CY 1108397 T1 CY1108397 T1 CY 1108397T1
- Authority
- CY
- Cyprus
- Prior art keywords
- ccr4
- fragment
- antibody
- recombinant antibody
- cell
- Prior art date
Links
- 239000012634 fragment Substances 0.000 title abstract 2
- 238000000034 method Methods 0.000 abstract 5
- 210000004027 cell Anatomy 0.000 abstract 4
- 101710149863 C-C chemokine receptor type 4 Proteins 0.000 abstract 3
- 102100032976 CCR4-NOT transcription complex subunit 6 Human genes 0.000 abstract 3
- 102000008394 Immunoglobulin Fragments Human genes 0.000 abstract 3
- 108010021625 Immunoglobulin Fragments Proteins 0.000 abstract 3
- 239000000032 diagnostic agent Substances 0.000 abstract 2
- 229940039227 diagnostic agent Drugs 0.000 abstract 2
- 239000003814 drug Substances 0.000 abstract 2
- 229940124597 therapeutic agent Drugs 0.000 abstract 2
- 230000001225 therapeutic effect Effects 0.000 abstract 2
- 101000738584 Homo sapiens C-C chemokine receptor type 4 Proteins 0.000 abstract 1
- 230000016396 cytokine production Effects 0.000 abstract 1
- 238000001514 detection method Methods 0.000 abstract 1
- 201000005787 hematologic cancer Diseases 0.000 abstract 1
- 208000024200 hematopoietic and lymphoid system neoplasm Diseases 0.000 abstract 1
- 102000043444 human CCR4 Human genes 0.000 abstract 1
- 230000001900 immune effect Effects 0.000 abstract 1
- 208000026278 immune system disease Diseases 0.000 abstract 1
- 230000002401 inhibitory effect Effects 0.000 abstract 1
- 230000001404 mediated effect Effects 0.000 abstract 1
Classifications
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/543—Immunoassay; Biospecific binding assay; Materials therefor with an insoluble carrier for immobilising immunochemicals
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/46—Hybrid immunoglobulins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A61P27/14—Decongestants or antiallergics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2866—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for cytokines, lymphokines, interferons
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/565—Complementarity determining region [CDR]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
- C07K2317/732—Antibody-dependent cellular cytotoxicity [ADCC]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
- G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
- G01N2333/78—Connective tissue peptides, e.g. collagen, elastin, laminin, fibronectin, vitronectin, cold insoluble globulin [CIG]
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Immunology (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmacology & Pharmacy (AREA)
- General Chemical & Material Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Molecular Biology (AREA)
- Biochemistry (AREA)
- Hematology (AREA)
- Urology & Nephrology (AREA)
- Biomedical Technology (AREA)
- Pulmonology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Biophysics (AREA)
- Genetics & Genomics (AREA)
- Pathology (AREA)
- Analytical Chemistry (AREA)
- Biotechnology (AREA)
- Cell Biology (AREA)
- Microbiology (AREA)
- General Physics & Mathematics (AREA)
- Food Science & Technology (AREA)
- Physics & Mathematics (AREA)
- Oncology (AREA)
- Ophthalmology & Optometry (AREA)
- Dermatology (AREA)
- Peptides Or Proteins (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
Abstract
Ανασυνδυασμένο αντίσωμα ή το θραύσμα αντισώματος αυτού το οποίο ειδικώς αντιδρά με εξωκυτταρικό πεδίο ανθρώπινης CCR4. DNA το οποίο κωδικοποιεί το ανασυνδυασμένο αντίσωμα ή το θραύσμα αντισώματος αυτού. Μέθοδος παρασκευής του ανασυνδυασμένου αντισώματος ή του θραύσματος αντισώματος αυτού. Μέθοδος ανίχνευσης ανοσολογικώς CCR4. Μέθοδος ανίχνευσης ανοσολογικώς ενός κυττάρου το οποίο εκφράζει CCR4 επί της επιφανείας του κυττάρου. Μέθοδος αφαίρεσης κυττάρου που εκφράζει CCR4 επί της επιφανείας κυττάρου και μέθοδος αναστολής παραγωγής Th2 κυτοκίνης που περιλαμβάνει χρήση του ανασυνδυασμένου αντισώματος ή θραύσματος αντισώματος αυτού. Θεραπευτικός ή διαγνωστικός παράγων για προκαλούμενες από Th2 άνοσες ασθένειες και θεραπευτικός ή διαγνωστικός παράγων για καρκίνο αίματος.
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2000059508 | 2000-03-03 | ||
| JP2000401563 | 2000-12-28 | ||
| EP01908280A EP1270595B1 (en) | 2000-03-03 | 2001-03-02 | Anti ccr4 antibody and its fragment |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CY1108397T1 true CY1108397T1 (el) | 2014-02-12 |
Family
ID=26586785
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CY20081101104T CY1108397T1 (el) | 2000-03-03 | 2008-10-06 | Αντι-ccr4 αντισωμα και θραυσμα αυτου |
Country Status (15)
| Country | Link |
|---|---|
| US (4) | US6989145B2 (el) |
| EP (2) | EP1270595B1 (el) |
| JP (1) | JP3926153B2 (el) |
| KR (1) | KR100890873B1 (el) |
| CN (1) | CN100455599C (el) |
| AT (1) | ATE402192T1 (el) |
| AU (2) | AU2001236073B2 (el) |
| CA (1) | CA2401491C (el) |
| CY (1) | CY1108397T1 (el) |
| DE (1) | DE60134962D1 (el) |
| DK (1) | DK1270595T3 (el) |
| ES (1) | ES2309050T3 (el) |
| PT (1) | PT1270595E (el) |
| SI (1) | SI1270595T1 (el) |
| WO (1) | WO2001064754A1 (el) |
Families Citing this family (51)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US7183387B1 (en) | 1999-01-15 | 2007-02-27 | Genentech, Inc. | Polypeptide variants with altered effector function |
| AU3672800A (en) * | 1999-04-09 | 2000-11-14 | Kyowa Hakko Kogyo Co. Ltd. | Method for controlling the activity of immunologically functional molecule |
| FR2807767B1 (fr) | 2000-04-12 | 2005-01-14 | Lab Francais Du Fractionnement | Anticorps monoclonaux anti-d |
| US6946292B2 (en) * | 2000-10-06 | 2005-09-20 | Kyowa Hakko Kogyo Co., Ltd. | Cells producing antibody compositions with increased antibody dependent cytotoxic activity |
| HU231090B1 (hu) | 2000-10-06 | 2020-07-28 | Kyowa Kirin Co., Ltd. | Antitest-kompozíciót termelő sejt |
| MXPA03008001A (es) * | 2001-03-06 | 2004-10-15 | Dow Chemical Co | Celula vegetal que tiene funcion de adicion de cadena de azucar tipo animal. |
| MXPA03009797A (es) * | 2001-04-26 | 2004-01-29 | Biogen Inc | ANTICUERPOS PARA BLOQUEO DE PROTEiNA CRIPTO Y USO DE LOS MISMOS. |
| US7582299B2 (en) * | 2001-04-26 | 2009-09-01 | Biogen Idec Ma Inc. | Cripto-specific antibodies |
| KR100959248B1 (ko) * | 2001-08-31 | 2010-05-26 | 교와 핫꼬 기린 가부시키가이샤 | 사람형 ｃｄｒ-이식 항체 및 이의 항체 단편 |
| CA2469082A1 (en) * | 2001-12-04 | 2003-06-12 | Raj K. Puri | Chimeric molecule for the treatment of th2-like cytokine mediated disorders |
| US20050095242A1 (en) * | 2002-02-28 | 2005-05-05 | Ryuzo Ueda | Diagnostics and remedies for interstitial pneumonia |
| WO2003084569A1 (en) | 2002-04-09 | 2003-10-16 | Kyowa Hakko Kogyo Co., Ltd. | Drug containing antibody composition |
| WO2004072646A1 (en) * | 2003-02-13 | 2004-08-26 | Bayer Healthcare Ag | Diagnostics and therapeutics for diseases associated with g protein-coupled receptor 5 (gpr5) |
| CA2529945A1 (en) * | 2003-06-27 | 2005-01-06 | Biogen Idec Ma Inc. | Use of hydrophobic-interaction-chromatography or hinge-region modifications for the production of homogeneous antibody-solutions |
| FR2858235B1 (fr) | 2003-07-31 | 2006-02-17 | Lab Francais Du Fractionnement | Utilisation d'anticorps optimises en adcc pour traiter les patients faibles repondeurs |
| EP1698640B2 (en) | 2003-10-01 | 2019-06-19 | Kyowa Hakko Kirin Co., Ltd. | Method of stabilizing antibody and stabilized solution-type antibody preparation |
| US20050287138A1 (en) * | 2003-10-08 | 2005-12-29 | Kyowa Hakko Kogyo Co., Ltd. | CCR4-specific antibody composition |
| FR2861395B1 (fr) | 2003-10-23 | 2006-02-17 | Lab Francais Du Fractionnement | Facteur viii viralement securise a faible teneur en multimeres superieurs |
| DE602004029934D1 (de) | 2003-12-04 | 2010-12-16 | Kyowa Hakko Kirin Co Ltd | Einen genetisch modifizierten antikörper gegen chemokin-rezeptor-ccr4 enthaltendes medikament |
| JPWO2005053742A1 (ja) * | 2003-12-04 | 2007-06-28 | 協和醗酵工業株式会社 | 抗体組成物を含有する医薬 |
| ES2775204T3 (es) | 2003-12-23 | 2020-07-24 | Genentech Inc | Nuevos anticuerpos anti IL13 y usos de los mismos |
| US20060034841A1 (en) * | 2004-06-07 | 2006-02-16 | Kyowa Hakko Kogyo Co., Ltd. | Method of depleting regulatory T cell |
| KR20070100346A (ko) | 2005-01-05 | 2007-10-10 | 바이오겐 아이덱 엠에이 인코포레이티드 | 크립토 결합 분자 |
| WO2009001840A1 (ja) * | 2007-06-25 | 2008-12-31 | Forerunner Pharma Research Co., Ltd. | ADCC活性又はCDC活性を有する抗Prominin-1抗体 |
| GB0718167D0 (en) | 2007-09-18 | 2007-10-31 | Cancer Rec Tech Ltd | Cancer marker and therapeutic target |
| JP5552630B2 (ja) * | 2008-10-24 | 2014-07-16 | 学校法人 聖マリアンナ医科大学 | Ｈｔｌｖ−ｉ関連脊髄症を治療または予防するための医薬、およびｈｔｌｖ−ｉ関連脊髄症の患者に対する抗体療法の効果を試験する方法 |
| GB0909906D0 (en) | 2009-06-09 | 2009-07-22 | Affitech As | Antibodies |
| JP2013505944A (ja) * | 2009-09-24 | 2013-02-21 | シアトル ジェネティックス， インコーポレイテッド | Ｄｒ５リガンド薬物結合体 |
| AU2011222012C1 (en) | 2010-03-02 | 2015-02-26 | Kyowa Kirin Co., Ltd. | Modified antibody composition |
| GB201020738D0 (en) | 2010-12-07 | 2011-01-19 | Affitech Res As | Antibodies |
| US10266599B2 (en) | 2010-12-07 | 2019-04-23 | Cancer Research Technology Limited | Antibodies which bind to the human CC chemokine receptor 4 and uses thereof |
| WO2012083132A2 (en) | 2010-12-16 | 2012-06-21 | Genentech, Inc. | Diagnosis and treatments relating to th2 inhibition |
| HUE041335T2 (hu) | 2011-03-29 | 2019-05-28 | Roche Glycart Ag | Antitest FC-variánsok |
| EP2723380B1 (en) | 2011-06-24 | 2019-08-21 | Stephen D. Gillies | Light chain immunoglobulin fusion proteins and methods of use thereof |
| US8790651B2 (en) | 2011-07-21 | 2014-07-29 | Zoetis Llc | Interleukin-31 monoclonal antibody |
| US20130280282A1 (en) * | 2012-04-24 | 2013-10-24 | Daiichi Sankyo Co., Ltd. | Dr5 ligand drug conjugates |
| BR112015000068A2 (pt) | 2012-07-06 | 2017-08-08 | Kyowa Hakko Kirin Co Ltd | método terapêutico e medicamento para mielopatia associada a htlv-1 (ham) |
| MX361337B (es) | 2012-07-13 | 2018-12-04 | Roche Glycart Ag | Anticuerpos biespecificos anti-factor de crecimiento endotelial vascular humano (vegf) / anti-angiopoyetina-2 humana (ang-2) y su uso en el tratamiento de enfermedades vasculares oculares. |
| ES2915378T3 (es) | 2013-09-13 | 2022-06-22 | Hoffmann La Roche | Procedimientos para detectar y cuantificar una proteína de célula huésped en líneas celulares |
| NZ756750A (en) | 2013-09-13 | 2022-05-27 | Genentech Inc | Methods and compositions comprising purified recombinant polypeptides |
| JP6795505B2 (ja) | 2014-10-06 | 2020-12-02 | デイナ ファーバー キャンサー インスティチュート，インコーポレイテッド | ヒト化ｃｃケモカイン受容体４（ｃｃｒ４）抗体およびその使用法 |
| AU2016293667A1 (en) | 2015-07-14 | 2018-01-04 | Kyowa Kirin Co., Ltd. | A therapeutic agent for a tumor comprising an IDO inhibitor administered in combination with an antibody |
| EP3393663B1 (en) | 2015-12-22 | 2021-04-14 | 3M Innovative Properties Company | Method of partitioning an aqueous test sample |
| JP7461741B2 (ja) | 2016-06-20 | 2024-04-04 | カイマブ・リミテッド | 抗ｐｄ－ｌ１およびｉｌ－２サイトカイン |
| US12053512B2 (en) | 2016-12-08 | 2024-08-06 | Nantbio, Inc. | Method of validating the triggering of an immune response to a neoepitope of a tumor with t-cells |
| WO2018156180A1 (en) | 2017-02-24 | 2018-08-30 | Kindred Biosciences, Inc. | Anti-il31 antibodies for veterinary use |
| CA3093539A1 (en) | 2018-03-16 | 2019-09-19 | Zoetis Services Llc | Interleukin-31 monoclonal antibodies for veterinary use |
| EP3765069A1 (en) | 2018-03-16 | 2021-01-20 | Zoetis Services LLC | Peptide vaccines against interleukin-31 |
| EP3773717A4 (en) * | 2018-03-29 | 2022-05-11 | REMD Biotherapeutics, Inc. | TREATMENT OF AUTOIMMUNE AND INFLAMMATION DISEASES WITH ANTIBODIES THAT BIND INTERLEUKIN-17A (IL-17A). |
| CA3119467A1 (en) | 2018-11-20 | 2020-05-28 | Cornell University | Macrocyclic complexes of radionuclides and their use in radiotherapy of cancer |
| WO2025149667A1 (en) | 2024-01-12 | 2025-07-17 | Pheon Therapeutics Ltd | Antibody drug conjugates and uses thereof |
Family Cites Families (22)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US19341A (en) * | 1858-02-16 | Louis beauche | ||
| US160015A (en) * | 1875-02-23 | Improvement in devices for cutting out sheet-metal washers | ||
| US187930A (en) * | 1877-02-27 | Improvement in processes of preserving meat | ||
| CU22545A1 (es) * | 1994-11-18 | 1999-03-31 | Centro Inmunologia Molecular | Obtención de un anticuerpo quimérico y humanizado contra el receptor del factor de crecimiento epidérmico para uso diagnóstico y terapéutico |
| JPH02257891A (ja) | 1989-03-31 | 1990-10-18 | Kyowa Hakko Kogyo Co Ltd | 組換え動物細胞による蛋白質の製造 |
| US5914110A (en) | 1993-09-07 | 1999-06-22 | Smithkline Beecham Corporation | Recombinant IL4 antibodies useful in treatment of IL4 mediated disorders |
| JPH0853355A (ja) | 1994-08-12 | 1996-02-27 | Taisho Pharmaceut Co Ltd | Ｉｌ−５産生抑制剤 |
| GB9501683D0 (en) | 1995-01-27 | 1995-03-15 | Glaxo Group Ltd | Substances and their uses |
| PL318594A1 (en) * | 1995-06-07 | 1997-06-23 | Icos Corp | Chemokine and analogues thereof originating from macrophages |
| US6498015B1 (en) * | 1995-06-07 | 2002-12-24 | Icos Corporation | Methods of identifying agents that modulate the binding between MDC and an MDC receptor |
| CN1241944C (zh) | 1995-09-11 | 2006-02-15 | 协和发酵工业株式会社 | 抗人白介素－5受体α链的抗体 |
| IL125658A0 (en) | 1997-08-18 | 1999-04-11 | Hoffmann La Roche | Ccr-3 receptor antagonists |
| EP1030662B1 (en) | 1997-11-12 | 2006-08-02 | F. Hoffmann-La Roche Ag | Treatment of t-helper cell type 2 mediated immune diseases with retinoid antagonists |
| US6355244B1 (en) | 1997-11-17 | 2002-03-12 | University Of Kentucky Research Foundation | Methods and compositions for the treatment of psoriasis |
| KR20010083069A (ko) | 1998-06-26 | 2001-08-31 | 나가야마 오사무 | 고칼슘혈증치료제 |
| US6245332B1 (en) * | 1999-01-15 | 2001-06-12 | The Board Of Trustees Of The Leland Stanford Junior University | Modulation of systemic memory T cell trafficking |
| US6488930B1 (en) | 1999-01-15 | 2002-12-03 | Millennium Pharmaceuticals, Inc. | Anti-CCR4 antibodies and methods of use therefor |
| EP1050307A1 (en) * | 1999-05-06 | 2000-11-08 | Applied Research Systems ARS Holding N.V. | CCR4 antagonists in sepsis |
| KR100959248B1 (ko) | 2001-08-31 | 2010-05-26 | 교와 핫꼬 기린 가부시키가이샤 | 사람형 ｃｄｒ-이식 항체 및 이의 항체 단편 |
| US20050287138A1 (en) * | 2003-10-08 | 2005-12-29 | Kyowa Hakko Kogyo Co., Ltd. | CCR4-specific antibody composition |
| DE602004029934D1 (de) * | 2003-12-04 | 2010-12-16 | Kyowa Hakko Kirin Co Ltd | Einen genetisch modifizierten antikörper gegen chemokin-rezeptor-ccr4 enthaltendes medikament |
| US20060034841A1 (en) * | 2004-06-07 | 2006-02-16 | Kyowa Hakko Kogyo Co., Ltd. | Method of depleting regulatory T cell |
-
2001
- 2001-03-02 AU AU2001236073A patent/AU2001236073B2/en active Active
- 2001-03-02 AT AT01908280T patent/ATE402192T1/de active
- 2001-03-02 CN CNB018059902A patent/CN100455599C/zh not_active Expired - Lifetime
- 2001-03-02 AU AU3607301A patent/AU3607301A/xx active Pending
- 2001-03-02 ES ES01908280T patent/ES2309050T3/es not_active Expired - Lifetime
- 2001-03-02 DK DK01908280T patent/DK1270595T3/da active
- 2001-03-02 PT PT01908280T patent/PT1270595E/pt unknown
- 2001-03-02 EP EP01908280A patent/EP1270595B1/en not_active Expired - Lifetime
- 2001-03-02 SI SI200130859T patent/SI1270595T1/sl unknown
- 2001-03-02 CA CA2401491A patent/CA2401491C/en not_active Expired - Lifetime
- 2001-03-02 EP EP08013028A patent/EP1992644A1/en not_active Withdrawn
- 2001-03-02 KR KR1020027011583A patent/KR100890873B1/ko not_active Expired - Lifetime
- 2001-03-02 WO PCT/JP2001/001656 patent/WO2001064754A1/ja not_active Ceased
- 2001-03-02 US US09/796,744 patent/US6989145B2/en not_active Expired - Lifetime
- 2001-03-02 DE DE60134962T patent/DE60134962D1/de not_active Expired - Lifetime
- 2001-03-02 JP JP2001564247A patent/JP3926153B2/ja not_active Expired - Lifetime
-
2005
- 2005-03-31 US US11/094,718 patent/US7666418B2/en not_active Expired - Fee Related
-
2008
- 2008-10-06 CY CY20081101104T patent/CY1108397T1/el unknown
-
2010
- 2010-01-08 US US12/684,651 patent/US8197814B2/en not_active Expired - Fee Related
-
2012
- 2012-06-08 US US13/492,465 patent/US8632996B2/en not_active Expired - Fee Related
Also Published As
| Publication number | Publication date |
|---|---|
| US7666418B2 (en) | 2010-02-23 |
| SI1270595T1 (sl) | 2008-12-31 |
| DE60134962D1 (de) | 2008-09-04 |
| WO2001064754A1 (en) | 2001-09-07 |
| AU2001236073B2 (en) | 2006-10-19 |
| US6989145B2 (en) | 2006-01-24 |
| KR20020089377A (ko) | 2002-11-29 |
| EP1270595A4 (en) | 2005-07-27 |
| EP1270595A1 (en) | 2003-01-02 |
| US20050187380A1 (en) | 2005-08-25 |
| US20020098527A1 (en) | 2002-07-25 |
| PT1270595E (pt) | 2008-09-16 |
| CA2401491C (en) | 2011-07-05 |
| CN100455599C (zh) | 2009-01-28 |
| KR100890873B1 (ko) | 2009-03-31 |
| US20120276090A1 (en) | 2012-11-01 |
| ATE402192T1 (de) | 2008-08-15 |
| DK1270595T3 (da) | 2008-11-10 |
| EP1270595B1 (en) | 2008-07-23 |
| AU3607301A (en) | 2001-09-12 |
| CA2401491A1 (en) | 2001-09-07 |
| ES2309050T3 (es) | 2008-12-16 |
| US8632996B2 (en) | 2014-01-21 |
| US8197814B2 (en) | 2012-06-12 |
| US20100221178A1 (en) | 2010-09-02 |
| CN1407993A (zh) | 2003-04-02 |
| JP3926153B2 (ja) | 2007-06-06 |
| EP1992644A1 (en) | 2008-11-19 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CY1108397T1 (el) | Αντι-ccr4 αντισωμα και θραυσμα αυτου | |
| CY1123667T1 (el) | Παρασκευασμα ανοσοσφαιρινης και μεθοδος παρασκευης αυτου | |
| DE69703121D1 (de) | Verfahren und zusammensetzungen zur verhinderung von entzündungen und angiogenese enthaltend säugetieren cd97 alpha untereinheit | |
| GR1000477B (el) | Νεο μονοκλωνικο αντισωμα κατα νεου αντιγονου που σχετιζεται με ανθρωπινους ογκους. | |
| CY1108765T1 (el) | ΑΓΩΓΗ ME ΑΝΤΙΣΩΜΑΤΑ ANTI-ErbB2 | |
| DE69730971D1 (de) | Vorrichtung zur verbesserung der transdermalen verabreichung von medikamenten oder der abnahme von körperflüssigkeiten | |
| CY1112171T1 (el) | Μτβ32α αντιγονο μυκοβακτηριδιου της φυματιωσης με απενεργοποιημενη δραστικη θεση και πρωτεϊνες συντηξης αυτου | |
| TR200002731T2 (tr) | Proteolitik antikorların indüktör ve inhibitörlerinin tanımlanması, kompozisyonları ve kullanımları için metotlar | |
| FI881418A7 (fi) | Synteettiset peptidiantigeenit HIV-1 -infektion toteamiseksi. | |
| IS5998A (is) | Notkun mótefna til bólusetningar gegn krabbameini | |
| DE69204157D1 (de) | Verfahren zur bestimmung von anti-rns-antikörpern. | |
| NO980013L (no) | Preparater og fremgangsmåter for behandling av T-cellemedierte sykdommer | |
| CY1107921T1 (el) | Μεθοδος για την προγνωση της αθροιστικης επιβιωσης ασθενων | |
| CY1107636T1 (el) | Πρωτεϊνες moraxella catarrhalis | |
| EP1451552A4 (en) | FOR DETECTING DISORDERS OF BREAST SUITABLE REAGENTS AND METHODS | |
| DK0666985T3 (da) | Kompakteringsanalysemetode til vurdering af behandling af respiratoriske sygdomme | |
| FI910324A7 (fi) | Menetelmät ja testipakkaukset ihmisen leukosyyttiantigeeni-DNA:n havaitsemiseksi | |
| FR2608767B1 (fr) | Procede pour la detection et le dosage des anticorps anti-(sporozoaires de p. falciparum) dans le sang humain et trousses de diagnostic pour mettre en oeuvre ce procede | |
| IT8820433A0 (it) | Metodo per rilevare una incipiente resistenza ad agenti terapeutici in pazienti cancerosi. | |
| AU6454396A (en) | Method for detecting or monitoring the effectiveness of treament of t cell mediated diseases | |
| BR0318688A (pt) | polipeptìdeo para o diagnóstico e terapia de leishmania | |
| PT1244442E (pt) | Processo para deteccao de inibidores de sintese de nucleotidos com menos efeitos secundarios | |
| CY1113516T1 (el) | Νουκλεϊκο οξυ και αντιστοιχη πρωτεϊνη με ονομασια 158p1d7 χρησιμα στην αγωγη και ανιχνευση καρκινου ουροδοχου κυστης και αλλων καρκινων | |
| ATE251309T1 (de) | Verfahren zur bestimmung eines erhöhten sterblichkeitsrate | |
| IT213853Z2 (it) | Sonda monouso per la determinazione del ph vaginale. |